BSX · Insider Trading
Boston Scientific Corp.
Every open-market purchase and sale reported by BSX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Padraig Andrew O'Connor | EVP, Global Operations | MIXED | +604 | −$27.43K |
| 2026-08-26 | Susan E Morano | Director | Buy | +2,040 | +$100.41K |
| 2026-08-12 | Emily Woodworth | SVP, Global Controller and CAO | I | +2,930 | +$149.99K |
| 2026-08-11 | Jonathan Monson | EVP and CFO | I | +9,908 | +$499.96K |
| 2026-08-07 | David C Habiger | Director | Buy | +2,100 | +$99.94K |
| 2026-08-07 | David C Habiger | Director | Buy | +2,100 | +$99.94K |
| 2026-08-05 | Michael F Mahoney | Chairman, President & CEO | MIXED | +208,359 | +$10.07M |
| 2026-08-05 | David C Habiger | Director | Buy | +1,182 | +$56.89K |
| 2026-08-03 | Edward J Ludwig | Director | Buy | +5,000 | +$227.40K |
| 2026-08-03 | Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | I | +64,198 | +$3.00M |
| 2026-07-02 | Jonathan Monson | EVP and CFO | MIXED | +1,077 | −$43.49K |
| 2026-06-01 | Michael F Mahoney | Chairman, President & CEO | G | −386,755 | — |
| 2026-05-21 | David C Habiger | Director | Buy | +4,450 | +$251.10K |
| 2026-05-21 | Edward J Ludwig | Director | Buy | +3,580 | +$202.91K |
| 2026-05-21 | Cheryl Pegus | Director | Buy | +1,770 | +$99.99K |
| 2026-05-11 | David C Habiger | Director | A | +3,800 | — |
| 2026-05-11 | Edward J Ludwig | Director | A | +3,800 | — |
| 2026-05-11 | Jessica L Mega | Director | A | +3,800 | — |
| 2026-05-11 | Susan E Morano | Director | A | +5,081 | — |
| 2026-05-11 | Cheryl Pegus | Director | A | +5,081 deriv. | — |
| 2026-05-11 | Cathy R Smith | Director | A | +6,009 deriv. | — |
| 2026-05-11 | Christophe Pierre Weber | Director | A | +2,907 | — |
| 2026-05-11 | David S Wichmann | Director | A | +3,800 | — |
| 2026-05-11 | Ellen M Zane | Director | A | +3,800 | — |
| 2026-05-04 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | +1,095 | −$56.90K |
| 2026-05-04 | Padraig Andrew O'Connor | EVP, Global Operations | MIXED | +930 | −$49.27K |
| 2026-03-04 | Cathy R Smith | Director | A | +879 deriv. | — |
| 2026-03-04 | Christophe Pierre Weber | Director | A | +879 | — |
| 2026-03-04 | Susan E Morano | Director | A | +24 | — |
| 2026-03-04 | Cheryl Pegus | Director | A | +24 deriv. | — |
| 2026-03-03 | Emily Woodworth | SVP, Global Controller and CAO | MIXED | +466 | −$28.59K |
| 2026-02-27 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | I | +6,851 | +$519.03K |
| 2026-02-18 | Vance R Brown | EVP, GC and Corp. Secretary | MIXED | +19,839 | −$1.09M |
| 2026-02-18 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | +30,802 | −$2.09M |
| 2026-02-18 | Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | MIXED | +44,015 | −$2.76M |
| 2026-02-18 | Michael F Mahoney | Chairman, President & CEO | MIXED | +158,047 | −$11.06M |
| 2026-02-18 | Miriam O'Sullivan | SVP, Chief HR Officer | MIXED | +1,882 | −$61.28K |
| 2026-02-18 | Jonathan Monson | EVP and CFO | MIXED | +2,116 | −$126.89K |
| 2026-02-18 | Emily Woodworth | SVP, Global Controller and CAO | MIXED | +1,442 | −$94.83K |
| 2026-02-18 | Padraig Andrew O'Connor | EVP, Global Operations | MIXED | +1,608 | −$73.76K |
| 2026-02-17 | Vance R Brown | EVP, GC and Corp. Secretary | MIXED | +954 | −$36.17K |
| 2026-02-17 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | +1,390 | −$96.50K |
| 2026-02-17 | Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | MIXED | +1,850 | −$119.48K |
| 2026-02-17 | Michael F Mahoney | Chairman, President & CEO | MIXED | +7,078 | −$491.12K |
| 2026-02-17 | Jonathan Monson | EVP and CFO | MIXED | +581 | −$42.47K |
| 2026-02-17 | Padraig Andrew O'Connor | EVP, Global Operations | MIXED | +601 | −$33.87K |
| 2026-02-17 | Emily Woodworth | SVP, Global Controller and CAO | MIXED | +239 | −$17.94K |
| 2026-02-17 | Miriam O'Sullivan | SVP, Chief HR Officer | MIXED | +623 | −$25.05K |
| 2026-02-03 | Michael F Mahoney | Chairman, President & CEO | MIXED | −65,147 | −$12.57M |
| 2025-12-02 | Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | MIXED | — | −$1.33M |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael F Mahoney | Chairman, President & CEO | 1,612,143 | $72.63M |
| Daniel J. Brennan | EVP and CFO | 232,618 | $10.48M |
| Joseph Michael Fitzgerald | EVP & Group Pres, Cardiology | 219,141 | $9.87M |
| Arthur C Butcher | EVP& Grp Pres, MedSurg & APAC | 78,122 | $3.52M |
| John E Sununu | Director | 54,723 | $2.47M |
| Jeffrey B. Mirviss | EVP&Pres, Periph Intervent | 53,454 | $2.41M |
| Vance R Brown | EVP, GC and Corp. Secretary | 53,295 | $2.40M |
| Jonathan Monson | EVP and CFO | 48,971 | $2.21M |
| David S Wichmann | Director | 45,382 | $2.04M |
| Wendy Carruthers | EVP, Human Resources | 35,094 | $1.58M |
| Edward J Ludwig | Director | 30,359 | $1.37M |
| Ellen M Zane | Director | 27,934 | $1.26M |
| John Bradley Sorenson | EVP, Global Operations | 25,195 | $1.14M |
| Miriam O'Sullivan | SVP, Chief HR Officer | 18,334 | $825.95K |
| David C Habiger | Director | 17,160 | $773.06K |
| Susan E Morano | Director | 13,784 | $620.97K |
| Jessica L Mega | Director | 12,035 | $542.18K |
| Padraig Andrew O'Connor | EVP, Global Operations | 7,892 | $355.53K |
| Emily Woodworth | SVP, Global Controller and CAO | 6,053 | $272.69K |
| Christophe Pierre Weber | Director | 3,786 | $170.56K |
| Yoshiaki Fujimori | Director | 2,081 | $93.75K |
| Cheryl Pegus | Director | 1,770 | $79.74K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BSX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.